Potential drug takes aim at emerging Chikungunya virus
December 09, 2022
Daniel Streblow, Ph.D., is leading research to develop an antiviral treatment for the chronic, debilitating joint pain that 30% to 40% of people experience after becoming infected with the emerging Chikunguyna virus. Streblow says: “We have the potential to develop an antiviral that could be used to treat millions of people during large Chikungunya outbreaks and prevent long-term disease in people who are persistently affected by this debilitating disease."